loading
Acadia Pharmaceuticals Inc stock is traded at $16.87, with a volume of 4.75M. It is up +0.84% in the last 24 hours and up +3.69% over the past month. Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
See More
Previous Close:
$16.73
Open:
$16.51
24h Volume:
4.75M
Relative Volume:
3.22
Market Cap:
$2.81B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
-18.34
EPS:
-0.92
Net Cash Flow:
$80.53M
1W Performance:
-2.26%
1M Performance:
+3.69%
6M Performance:
+14.37%
1Y Performance:
-41.93%
1-Day Range:
Value
$16.49
$17.21
1-Week Range:
Value
$16.27
$17.86
52-Week Range:
Value
$14.15
$32.59

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
Name
Acadia Pharmaceuticals Inc
Name
Phone
858-558-2871
Name
Address
12830 EL CAMINO REAL, SAN DIEGO
Name
Employee
620
Name
Twitter
@acadiapharma
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
ACAD's Discussions on Twitter

Compare ACAD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
16.87 2.81B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-10-24 Resumed Raymond James Mkt Perform
Aug-07-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-27-24 Initiated BMO Capital Markets Outperform
Mar-12-24 Downgrade Mizuho Buy → Neutral
Mar-12-24 Reiterated Needham Buy
Jan-30-24 Initiated Robert W. Baird Outperform
Jan-24-24 Upgrade Needham Hold → Buy
Dec-19-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-14-23 Downgrade Deutsche Bank Buy → Hold
Dec-13-23 Initiated Citigroup Buy
Dec-12-23 Initiated Deutsche Bank Buy
Nov-06-23 Upgrade Mizuho Neutral → Buy
Oct-17-23 Initiated UBS Buy
Oct-10-23 Upgrade JP Morgan Neutral → Overweight
Jan-03-23 Upgrade Guggenheim Neutral → Buy
Nov-04-22 Downgrade Goldman Neutral → Sell
Nov-01-22 Initiated Loop Capital Hold
Aug-08-22 Downgrade Citigroup Buy → Neutral
Aug-05-22 Downgrade Citigroup Buy → Neutral
Jun-21-22 Downgrade Jefferies Buy → Underperform
Jun-16-22 Upgrade Jefferies Hold → Buy
Mar-16-22 Upgrade Canaccord Genuity Hold → Buy
Feb-09-22 Upgrade H.C. Wainwright Neutral → Buy
Jan-05-22 Upgrade Citigroup Neutral → Buy
Dec-21-21 Downgrade Guggenheim Buy → Neutral
Nov-01-21 Upgrade Guggenheim Neutral → Buy
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Jun-10-21 Initiated Berenberg Hold
Apr-07-21 Downgrade H.C. Wainwright Buy → Neutral
Apr-06-21 Downgrade Canaccord Genuity Buy → Hold
Apr-06-21 Downgrade Goldman Buy → Neutral
Apr-06-21 Downgrade Jefferies Buy → Hold
Apr-06-21 Downgrade Mizuho Buy → Neutral
Apr-05-21 Downgrade Raymond James Outperform → Mkt Perform
Mar-10-21 Downgrade BofA Securities Buy → Neutral
Mar-09-21 Downgrade Citigroup Buy → Neutral
Mar-09-21 Downgrade Guggenheim Buy → Neutral
Mar-09-21 Reiterated H.C. Wainwright Buy
Mar-09-21 Downgrade Raymond James Strong Buy → Outperform
Mar-09-21 Downgrade Stifel Buy → Hold
Dec-16-20 Initiated Mizuho Buy
Nov-16-20 Upgrade Raymond James Outperform → Strong Buy
Aug-25-20 Initiated Raymond James Outperform
Aug-20-20 Initiated Morgan Stanley Overweight
Jul-07-20 Upgrade Stifel Hold → Buy
Apr-16-20 Initiated Jefferies Buy
Mar-31-20 Upgrade Goldman Neutral → Buy
Mar-06-20 Initiated Citigroup Buy
Dec-16-19 Initiated Guggenheim Buy
Oct-24-19 Initiated Oppenheimer Perform
Oct-01-19 Initiated RBC Capital Mkts Outperform
Sep-13-19 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-10-19 Upgrade Canaccord Genuity Hold → Buy
Jul-23-19 Reiterated Needham Buy
Dec-10-18 Initiated Canaccord Genuity Hold
Sep-21-18 Upgrade Piper Jaffray Neutral → Overweight
Aug-09-18 Reiterated Stifel Hold
Aug-07-18 Initiated Stifel Hold
Aug-06-18 Downgrade Piper Jaffray Overweight → Neutral
Oct-06-17 Resumed Goldman Neutral
View All

Acadia Pharmaceuticals Inc Stock (ACAD) Latest News

pulisher
Dec 19, 2024

Acadia Pharmaceuticals to Present at J.P. Morgan Healthcare Conference: Pioneering CNS Treatment Innovations - StockTitan

Dec 19, 2024
pulisher
Dec 19, 2024

ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 2.9%What's Next? - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Schizophrenia Market Predicted to See Upsurge Through 2034, - openPR

Dec 19, 2024
pulisher
Dec 17, 2024

State Street Corp Acquires 173,084 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

Acadia Pharmaceuticals Awards Stock Options, RSUs to New Hires in Neuroscience Expansion - StockTitan

Dec 16, 2024
pulisher
Dec 16, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Position Reduced by Fmr LLC - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

ACADIA Pharmaceuticals' SWOT analysis: stock outlook amid Daybue challenges - Investing.com

Dec 16, 2024
pulisher
Dec 15, 2024

Acadia closes on $150M FDA voucher sale - MSN

Dec 15, 2024
pulisher
Dec 14, 2024

Y Intercept Hong Kong Ltd Sells 39,245 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Dec 14, 2024
pulisher
Dec 13, 2024

Neo Ivy Capital Management Reduces Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Dec 13, 2024
pulisher
Dec 11, 2024

Acadia Pharmaceuticals Secures $150M Windfall from Priority Review Voucher Sale, Boosts R&D Pipeline - StockTitan

Dec 11, 2024
pulisher
Dec 11, 2024

Pharma Pulse 12/10/24: Did Industry Fumble the DSCSA Deadline? Operationalizing Bispecifics Resources & more - Pharmaceutical Executive

Dec 11, 2024
pulisher
Dec 09, 2024

Postoperative Pain Market: Market Outlook, Epidemiology Insights, Therapies, Key Companies in the Market | ACADIA Pharmaceuticals, Adynxx, Apsen Farmaceutica, Arthritis Innovation Corporation, Cali - Barchart

Dec 09, 2024
pulisher
Dec 09, 2024

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer - BioSpace

Dec 09, 2024
pulisher
Dec 09, 2024

Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead - FiercePharma

Dec 09, 2024
pulisher
Dec 09, 2024

Acadia Buys Saniona Tremor Drug - San Diego Business Journal

Dec 09, 2024
pulisher
Dec 08, 2024

Walleye Capital LLC Has $628,000 Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Dec 08, 2024
pulisher
Dec 08, 2024

Brokerages Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56 - MarketBeat

Dec 08, 2024
pulisher
Dec 06, 2024

Pharma Pulse 12/5/24: Gaps in Publicly Funded Non-Inferiority Clinical Trials, Are GLP-1s Eliminating the Need for Bariatric Surgery? & more - Pharmaceutical Executive

Dec 06, 2024
pulisher
Dec 06, 2024

The Manufacturers Life Insurance Company Sells 48,809 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Dec 06, 2024
pulisher
Dec 05, 2024

Jacobs Levy Equity Management Inc. Sells 143,688 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Dec 05, 2024
pulisher
Dec 05, 2024

BNP Paribas Financial Markets Boosts Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Dec 05, 2024
pulisher
Dec 04, 2024

Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options - MSN

Dec 04, 2024
pulisher
Dec 03, 2024

Ryan Reynolds' Latest Film: 'More To Parkinson's' 08/19/2024 - MediaPost Communications

Dec 03, 2024
pulisher
Dec 03, 2024

Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Dec 03, 2024
pulisher
Dec 03, 2024

Erste Asset Management GmbH Makes New $3.80 Million Investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Dec 03, 2024
pulisher
Dec 03, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Significant Growth in Short Interest - MarketBeat

Dec 03, 2024
pulisher
Dec 02, 2024

The week in deals: Acadia taps Saniona for GABRA3 modulator, and more - BioCentury

Dec 02, 2024
pulisher
Dec 02, 2024

Rockefeller Capital Management L.P. Has $17.53 Million Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Dec 02, 2024
pulisher
Dec 02, 2024

Edgestream Partners L.P. Raises Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Dec 02, 2024
pulisher
Dec 02, 2024

37,683 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Purchased by Intech Investment Management LLC - MarketBeat

Dec 02, 2024
pulisher
Dec 02, 2024

Zacks Research Has Strong Estimate for ACAD FY2024 Earnings - MarketBeat

Dec 02, 2024
pulisher
Nov 30, 2024

Acadia signs licensing deal for essential tremor drug candidate - MSN

Nov 30, 2024
pulisher
Nov 30, 2024

Fred Alger Management LLC Raises Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Nov 30, 2024
pulisher
Nov 29, 2024

Fisher Asset Management LLC Acquires 31,980 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Nov 29, 2024
pulisher
Nov 28, 2024

ACADIA Pharmaceuticals' SWOT analysis: stock outlook mixed as DAYBUE launch faces hurdles - Investing.com India

Nov 28, 2024
pulisher
Nov 28, 2024

Acadia signs deal with Saniona for SAN711 rights - The Pharma Letter

Nov 28, 2024
pulisher
Nov 28, 2024

Saniona’s CEO: “The deal with Acadia is significant”BioStock - BioStock - Connecting Innovation and Capital

Nov 28, 2024
pulisher
Nov 27, 2024

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET (NASDAQ:ACAD) - Seeking Alpha

Nov 27, 2024
pulisher
Nov 27, 2024

Saniona Cash Worries Ease With Acadia Neuro Biobucks Pact - Citeline

Nov 27, 2024
pulisher
Nov 27, 2024

ACAD Signs License Deal With Saniona for Rights to Neurology Drug - Yahoo Finance

Nov 27, 2024
pulisher
Nov 27, 2024

Acadia licenses Saniona’s SAN711 for essential tremor in deal worth up to $610m - World Pharmaceutical Frontiers

Nov 27, 2024
pulisher
Nov 27, 2024

Acadia snaps up an essential tremor drug after field’s summer setbacks - Endpoints News

Nov 27, 2024
pulisher
Nov 27, 2024

Acadia signs agreement with Saniona to commercialise SAN711 - Pharmaceutical Technology

Nov 27, 2024
pulisher
Nov 27, 2024

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711 - BioSpace

Nov 27, 2024
pulisher
Nov 27, 2024

Acadia secures Saniona's experimental tremor drug in $600M deal - FirstWord Pharma

Nov 27, 2024
pulisher
Nov 27, 2024

Saniona signs license agreement with Acadia Pharmaceuticals for SAN711 - Marketscreener.com

Nov 27, 2024
pulisher
Nov 26, 2024

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for San711 - Marketscreener.com

Nov 26, 2024
pulisher
Nov 26, 2024

Acadia licenses novel treatment for essential tremor By Investing.com - Investing.com Nigeria

Nov 26, 2024
pulisher
Nov 26, 2024

Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711 - MarketWatch

Nov 26, 2024
pulisher
Nov 26, 2024

Acadia nabs rights to Saniona's tremor asset in $582M biobucks deal - Fierce Biotech

Nov 26, 2024

Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Cap:     |  Volume (24h):